These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 38948747)

  • 1. ACE2 decoy Fc-fusions and bi-specific killer engager (BiKEs) require Fc engagement for
    Dick JK; Hicks D; Krishna VD; Sangala JA; Zandstra BT; Baehr C; Verbeek JS; Cragg MS; Cheeran MC; Pravetoni M; Hart GT
    bioRxiv; 2024 Jun; ():. PubMed ID: 38948747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.
    Ferrari M; Mekkaoui L; Ilca FT; Akbar Z; Bughda R; Lamb K; Ward K; Parekh F; Karattil R; Allen C; Wu P; Baldan V; Mattiuzzo G; Bentley EM; Takeuchi Y; Sillibourne J; Datta P; Kinna A; Pule M; Onuoha SC
    J Virol; 2021 Sep; 95(19):e0068521. PubMed ID: 34287040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection.
    Lu M; Yao W; Li Y; Ma D; Zhang Z; Wang H; Tang X; Wang Y; Li C; Cheng D; Lin H; Yin Y; Zhao J; Zhong G
    Microbiol Spectr; 2023 Aug; 11(4):e0110023. PubMed ID: 37395664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic option for current and future coronaviruses outbreaks.
    Alfaleh MA; Alsulaiman RM; Almahboub SA; Nezamuldeen L; Zawawi A; Aljehani ND; Yasir M; Abdulal RH; Alkhaldi R; Helal A; Alamri SS; Malki J; Alhabbab RY; Abujamel TS; Alhakamy NA; Alnami A; Algaissi A; Hassanain M; Hashem AM
    Antib Ther; 2024 Jan; 7(1):53-66. PubMed ID: 38371953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective Efficacy of Novel Engineered Human ACE2-Fc Fusion Protein Against Pan-SARS-CoV-2 Infection In Vitro and in Vivo.
    Yu B; Drelich A; Hsu J; Tat V; Peng BH; Wei Q; Wang J; Wang H; Wages J; Mendelsohn AR; Larrick JW; Tseng CT
    J Med Chem; 2023 Dec; 66(24):16646-16657. PubMed ID: 38100534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides.
    Llewellyn GN; Chen HY; Rogers GL; Huang X; Sell PJ; Henley JE; Cannon PM
    J Virol; 2023 Aug; 97(8):e0068423. PubMed ID: 37555663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo.
    Torchia JA; Tavares AH; Carstensen LS; Chen DY; Huang J; Xiao T; Mukherjee S; Reeves PM; Tu H; Sluder AE; Chen B; Kotton DN; Bowen RA; Saeed M; Poznansky MC; Freeman GJ
    Sci Adv; 2022 Dec; 8(49):eabq6527. PubMed ID: 36475798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection.
    Huang KY; Lin MS; Kuo TC; Chen CL; Lin CC; Chou YC; Chao TL; Pang YH; Kao HC; Huang RS; Lin S; Chang SY; Yang PC
    EMBO Mol Med; 2021 Jan; 13(1):e12828. PubMed ID: 33159417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models.
    Urano E; Itoh Y; Suzuki T; Sasaki T; Kishikawa JI; Akamatsu K; Higuchi Y; Sakai Y; Okamura T; Mitoma S; Sugihara F; Takada A; Kimura M; Nakao S; Hirose M; Sasaki T; Koketsu R; Tsuji S; Yanagida S; Shioda T; Hara E; Matoba S; Matsuura Y; Kanda Y; Arase H; Okada M; Takagi J; Kato T; Hoshino A; Yasutomi Y; Saito A; Okamoto T
    Sci Transl Med; 2023 Aug; 15(711):eadi2623. PubMed ID: 37647387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2.
    Wines BD; Kurtovic L; Trist HM; Esparon S; Lopez E; Chappin K; Chan LJ; Mordant FL; Lee WS; Gherardin NA; Patel SK; Hartley GE; Pymm P; Cooney JP; Beeson JG; Godfrey DI; Burrell LM; van Zelm MC; Wheatley AK; Chung AW; Tham WH; Subbarao K; Kent SJ; Hogarth PM
    Front Immunol; 2022; 13():889372. PubMed ID: 35967361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo.
    Havranek B; Lindsey GW; Higuchi Y; Itoh Y; Suzuki T; Okamoto T; Hoshino A; Procko E; Islam SM
    Commun Biol; 2023 May; 6(1):513. PubMed ID: 37173421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting SARS-CoV-2 infection through CAR-T-like bispecific T cell engagers incorporating ACE2.
    Dogan M; Kozhaya L; Placek L; Karabacak F; Yigit M; Unutmaz D
    Clin Transl Immunology; 2022; 11(10):e1421. PubMed ID: 36285327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity.
    Yao X; Zhang Z; Mei Q; Li S; Xing L; Long Y; Zhang D; Wang J; Wang X; Xie B; Yang B; Gao Y; Wu C; Meng Q
    Front Immunol; 2022; 13():1041860. PubMed ID: 36532082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo.
    Zhang Z; Zeng E; Zhang L; Wang W; Jin Y; Sun J; Huang S; Yin W; Dai J; Zhuang Z; Chen Z; Sun J; Zhu A; Li F; Cao W; Li X; Shi Y; Gan M; Zhang S; Wei P; Huang J; Zhong N; Zhong G; Zhao J; Wang Y; Shao W; Zhao J
    Cell Discov; 2021 Aug; 7(1):65. PubMed ID: 34385423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2.
    Verstraete MM; Heinkel F; Li J; Cao S; Tran A; Halverson EC; Gene R; Stangle E; Silva-Moreno B; Arrafi S; Bavananthasivam J; Fung M; Eji-Lasisi M; Masterman S; Xanthoudakis S; Dixit S; Babcook J; Clavette B; Fogg M; Escobar-Cabrera E
    MAbs; 2023; 15(1):2212415. PubMed ID: 37229608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses.
    Sims JJ; Lian S; Meggersee RL; Kasimsetty A; Wilson JM
    PLoS One; 2022; 17(8):e0271359. PubMed ID: 36006993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors.
    Alfaleh MA; Zawawi A; Al-Amri SS; Hashem AM
    MAbs; 2022; 14(1):2057832. PubMed ID: 35380919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering ACE2 decoy receptors to combat viral escapability.
    Arimori T; Ikemura N; Okamoto T; Takagi J; Standley DM; Hoshino A
    Trends Pharmacol Sci; 2022 Oct; 43(10):838-851. PubMed ID: 35902282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.